TY - JOUR
T1 - Epidemiology and staphylococcal cassette chromosome mec typing of methicillin-resistant Staphylococcus aureus isolates in Taiwan
T2 - A multicenter study
AU - Pan, Sung Ching
AU - Wang, Jann Tay
AU - Lauderdale, Tsai Ling
AU - Ko, Wen Chien
AU - Chen, Yao Shen
AU - Liu, Jien Wei
AU - Lau, Yeu Jun
AU - Wang, Li Hsin
AU - Liu, Ke Sun
AU - Liao, Chun Hsing
AU - Lin, San Yi
AU - Hu, Bor Shen
AU - Chang, Shan Chwen
PY - 2014/7
Y1 - 2014/7
N2 - Background/Purpose: After community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) was identified, new community-onset, healthcare-associated MRSA (HA-MRSA-CO) infections have been noticed as MRSA infection in patients with community-onset infection who have underlying conditions resulting in frequent exposure to the healthcare system. However, previous studies have not thoroughly investigated whether HA-MRSA-CO has characteristics resembling those of CA-MRSA or hospital-onset, healthcare-associated MRSA (HA-MRSA-HO) infection. Methods: A multicenter, retrospective study was conducted to analyze the clinical and microbiological data of patients with clinical isolates of MRSA from nine hospitals in Taiwan. Results: In total, 203 patients with MRSA isolates, including 27 patients with CA-MRSA (13.3%), 59 with HA-MRSA-CO (29.1%), and 117 with HA-MRSA-HO (57.6%), were studied. Compared to HA-MRSA-HO isolates, the CA-MRSA and HA-MRSA-CO isolates were associated with a higher proportion of skin and soft tissue infections (81.8% and 65.3% vs. 40.5%, p=. 0.001 and p=. 0.002) as well as lesser rate of resistance to ciprofloxacin (33.3% and 50.9% vs. 74.4%, p<. 0.001 and p=. 0.002), gentamicin (44.4% and 64.4% vs. 84.6%, p<. 0.001 and p=. 0.002), and trimethoprim/sulfamethoxazole (33.3% and 42.4% vs. 58.1%, p=. 0.02 and p=. 0.048), and a lower 30-day all-cause mortality rate (7.4% and 0% vs. 20.9%, p<. 0.001). Most of the CA-MRSA isolates were classified as staphylococcal cassette chromosome mec (SCC. mec) type VT (11/27, 40.7%), whereas most HA-MRSA-HO isolates were classified as SCC. mec type III (66/117, 56.4%). Conclusion: The CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO clinical isolates significantly differed in their clinical presentations and molecular characteristics.
AB - Background/Purpose: After community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) was identified, new community-onset, healthcare-associated MRSA (HA-MRSA-CO) infections have been noticed as MRSA infection in patients with community-onset infection who have underlying conditions resulting in frequent exposure to the healthcare system. However, previous studies have not thoroughly investigated whether HA-MRSA-CO has characteristics resembling those of CA-MRSA or hospital-onset, healthcare-associated MRSA (HA-MRSA-HO) infection. Methods: A multicenter, retrospective study was conducted to analyze the clinical and microbiological data of patients with clinical isolates of MRSA from nine hospitals in Taiwan. Results: In total, 203 patients with MRSA isolates, including 27 patients with CA-MRSA (13.3%), 59 with HA-MRSA-CO (29.1%), and 117 with HA-MRSA-HO (57.6%), were studied. Compared to HA-MRSA-HO isolates, the CA-MRSA and HA-MRSA-CO isolates were associated with a higher proportion of skin and soft tissue infections (81.8% and 65.3% vs. 40.5%, p=. 0.001 and p=. 0.002) as well as lesser rate of resistance to ciprofloxacin (33.3% and 50.9% vs. 74.4%, p<. 0.001 and p=. 0.002), gentamicin (44.4% and 64.4% vs. 84.6%, p<. 0.001 and p=. 0.002), and trimethoprim/sulfamethoxazole (33.3% and 42.4% vs. 58.1%, p=. 0.02 and p=. 0.048), and a lower 30-day all-cause mortality rate (7.4% and 0% vs. 20.9%, p<. 0.001). Most of the CA-MRSA isolates were classified as staphylococcal cassette chromosome mec (SCC. mec) type VT (11/27, 40.7%), whereas most HA-MRSA-HO isolates were classified as SCC. mec type III (66/117, 56.4%). Conclusion: The CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO clinical isolates significantly differed in their clinical presentations and molecular characteristics.
UR - http://www.scopus.com/inward/record.url?scp=84902796979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902796979&partnerID=8YFLogxK
U2 - 10.1016/j.jfma.2012.05.012
DO - 10.1016/j.jfma.2012.05.012
M3 - Article
C2 - 24961181
AN - SCOPUS:84902796979
SN - 0929-6646
VL - 113
SP - 409
EP - 416
JO - Journal of the Formosan Medical Association
JF - Journal of the Formosan Medical Association
IS - 7
ER -